Intraluminal Blockade of Cell-Surface CD74 and Glucose Regulated Protein 78 Prevents Substance P-Induced Bladder Inflammatory Changes in the Rat by Vera, Pedro L. et al.
Intraluminal Blockade of Cell-Surface CD74 and Glucose
Regulated Protein 78 Prevents Substance P-Induced
Bladder Inflammatory Changes in the Rat
Pedro L. Vera
1,2*, Xihai Wang
1,2, Richard J. Bucala
3, Katherine L. Meyer-Siegler
1,4
1The Bay Pines VA Healthcare System, Research & Development, Bay Pines, Florida, United States of America, 2Department of Surgery, Division of Urology, University of
South Florida, College of Medicine, Tampa, Florida, United States of America, 3Department of Internal Medicine, Yale University School of Medicine, New Haven,
Connecticut, United States of America, 4Department of Molecular Medicine, University of South Florida, College of Medicine, Tampa, Florida, United States of America
Abstract
Background: Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine constitutively expressed by
urothelial cells. During inflammatory stimuli, MIF is released into the lumen complexed to other proteins and these
complexes can bind to urothelial cell-surface receptors to activate signaling pathways. Since MIF is complexed to a1-
inhibitor III (A1-I3; a member of the a2-macroglubulin family) and glucose regulated protein 78 (GRP78) is a receptor for A1-
I3 the goals of this study were to determine if substance P elicits urothelial cell-surface expression of GRP78 and to assess
the functional role of CD74 (receptor for MIF) or GRP78 in substance P-induced bladder inflammatory changes.
Methodology/Principal Findings: Anesthetized male Sprague-Dawley rats received either saline or substance P (s.c.),
bladders were collected 1 hour after treatment and processed for histology or protein/mRNA. The expression of GRP78 at
urothelial cell-surface was determined by performing in vivo biotinylation of urothelial cell-surface proteins. Finally, in order
to determine the effects of receptor blockade on substance P-induced MIF release and inflammatory changes, rats received
either intraluminal antibodies to CD74, GRP78, both, or non-specific IgG (as a control). GRP78 and MIF immunostaining
was simultaneously visualized in umbrella cells only after substance P treatment. Immunoprecipitation studies showed
GRP78-MIF complexes increased after substance P while in vivo biotinylation confirmed substance P-induced GRP78 cell-
surface expression in urothelial cells. Intraluminal blockade of CD74 and/or GRP78 prevented substance P-induced changes,
including bladder edema, intraluminal MIF release by urothelial cells and production of inflammatory cytokines by urothelial
cells.
Conclusions/Significance: GRP78 is expressed on the surface of urothelial cells after substance P treatment where it can
bind MIF complexes. Blocking CD74 (receptor for MIF) and/or GRP78 prevented substance P-induced inflammatory changes
in bladder and urothelium, indicating that these urothelial receptors are effective targets for disrupting MIF-mediated
bladder inflammation.
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Introduction
Macrophage migration inhibitory factor (MIF), a pleiotropic
pro-inflammatory cytokine[1] found in many different cells
(including urothelium), is associated with experimental cystitis[2–
7] and urinary tract infection in humans[8]. MIF is released
(complexed to other proteins[8,9]) into the lumen during cystitis
and this process depends on activation of bladder afferent and
efferent nerves[7]. The source of released MIF is unknown,
however, since MIF is constitutively expressed in the basal and
intermediate layers of the urothelium[10], and MIF mRNA is
upregulated in the urothelium during inflammation[11], it is likely
that the urothelium is either responsible for MIF release during
cystitis or contributes a significant portion of the MIF released.
Examining changes in urothelial MIF content and also changes in
inflammatory markers in the urothelium would answer questions
about the source of released MIF during cystitis and would also
support an active role for the urothelium during inflammation.
This is an important question and would indicate that the
urothelium is an active respondent to bladder injury and
participates in inflammatory signal transduction[12].
Once released into the lumen, MIF and/or MIF-complexes
may bind cell-surface receptors (e.g. CD74[13]; CXCR4[14,15])
to activate pro-inflammatory signal transduction cascades and thus
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5835maintain or enhance bladder inflammation. In fact, both CD74 and
CXCR4 have been shown to be upregulated in the bladder during
cystitis [4,6,15]. Moreover, using an in vivobiotinylationprocedure,
we recently showed that substance P (SP) induces cell-surface
expression of CD74 in urothelial cells which allows MIF-CD74
binding[11].Thus,duringcystitisnotonlyisthereMIFreleasedinto
thelumenbutalsoexpressionofreceptorsonthesurfaceofurothelial
cellsthatbindtoMIFtomaintainorpromotebladderinflammation.
Accordingly, blocking MIF-receptor interactions may be a means to
pharmacologically disrupt bladder inflammation.
We showed in the rat that MIF is released complexed to a1-
inhibitor III (A1-I3; an acute phase protein in the a2 macroglobulin
family)[9] and we also showed that MIF and A1-I3 immunostaining
are observed simultaneously in umbrella cells after substance P (SP)
treatment[16]. Since glucose-regulated protein 78 (GRP78) is a
receptor for A1-I3[17], we hypothesized that SP elicits cell-surface
GRP78expressioninumbrellacellswiththeabilitytobindMIF-A1-
I3 complexes. GRP78 (an endoplasmic reticulum stress protein
activatedaspartoftheunfoldedproteinresponse[18])localizestothe
cell-surface and mediates signal transduction[17,19], although the
role of GRP78 in bladder inflammation is not known. Therefore, in
the present study we investigated the effects of SP on GRP78
expressioninurotheliumandthefunctionalroleofGRP78orCD74
(receptor for MIF recently shown by us to be expressed on the
urothelialcellsurfaceafterSPtreatment[11])onSP-inducedbladder
inflammation in rats.
In these experiments we aimed to: 1) examine SP-induced
GRP78 and MIF immunostaining in the urothelium; 2) examine
SP-induced MIF-GRP78 complexes in the bladder using co-
immunoprecipitation; 3) examine SP-induced urothelial cell-
surface expression of GRP78 using in vivo biotinylation of
urothelial cell-surface proteins and GRP78 immunoblotting; 4)
test effects of intraluminal blockade with antibodies to CD74 and
GRP78 on SP-induced bladder inflammation, urothelial MIF
release and inflammatory cytokine expression.
Results
Substance P-induced GRP78 and MIF immunostaining in
umbrella cells
Bladder sections from saline and SP-treated rats were
simultaneously exposed to MIF and GRP78 antibodies, visualized
using dual immunofluorescence and single fluorophore images
were overlaid. Sections where both primary antibodies had been
omitted showed no immunofluorescence (Fig. 1A–C; arrows
indicate luminal edge of urothelium). Similarly, omission of either
one of the secondary antibodies resulted in only the appropriate
fluorescence being observed (not shown). In saline treated rats,
MIF immunostaining was observed in basal and intermediate
layers of the urothelium as previously described (Fig 1D)[10];
while no GRP78 immunostaining was observed in the urothelium
(Fig. 1E) and thus the overlay (Fig. 1F) showed only MIF
immunostaining.
After SP treatment, on the other hand, both MIF (Fig. 1G;J) and
GRP78 (Fig. 1H;K) immunostaining were observed in the
urothelium. Umbrella cells, in particular, showed both (rendered
orange color after overlay and marked by asterisks in Fig 1I;L).
Umbrella cells containing only MIF (Fig 1I; green arrow) or only
GRP78 (Fig 1L; red arrow) were also visible. Intermediate and
basal cells were only MIF-positive (Fig 1I;L). In addition, the
lamina propia, where only MIF immunostaining was present, also
showed increased MIF immunostaining after SP treatment
(Fig. 1G;J arrowheads) compared to saline treatment.
Substance P-induced increase in bladder GRP78-MIF
complexes
We examined GRP78-MIF complexes in the bladder by
‘‘pulling down’’ GRP78 complexes in bladder homogenates,
electrophoresing the resultant proteins and performing western
blotting for MIF or for A1-I3. Figure 2A is representative of the
co-immunoprecipitation studies and shows a representative
experiment where the resultant proteins from the same samples
were assayed with MIF western blotting (left side of figure) or A1-
I3 western blotting (right side of the figure).
GRP78 co-immunoprecipitation of bladder homogenates
followed by MIF western-blotting showed a faint band at
approximately 12 kDa corresponding to MIF (Fig 2A; left side;
lane labeled Sal; marked by ##) after saline treatment and a
band of greater intensity is observed after SP treatment (Fig 2A;
left side; lane labeled SP). Recombinant MIF is included as a
positive control. Also, GRP78 co-immunoprecipitation of
bladder homogenates followed by A1-I3 western blotting (right
hand Fig 2A) showed several A1-I3 bands (as expected since
GRP78 is a receptor for A1-I3) at different molecular weights
(200, 130 and 80 kDa) indicating full-length and proteolytic
fragments of A1-I3, as reported before [9]. Absence of bands
at 12 kDa demonstrates that A1-I3 antibodies do not cross-
react with MIF. Bands at 130 and 80 kDa could be seen in
both MIF and A1-I3 western blots indicating MIF-A1-I3
complexes at these molecular weights as previously de-
scribed[9].
Substance P-induced Cell-surface expression of GRP78
Proteins expressed on the surface of urothelial cells were
detected by intraluminal in vivo biotinylation, a method we
described in detail recently[11]. After exposure of urothelial
cells to biotinylation reagent and collection of urothelial cells
(by scraping), the cells were homogenized and biotinylated
proteins (i.e. cell-surface proteins) were collected in an avidin
column. GRP78 co-immunoprecipitation of such biotinylated
proteins, electrophoresis and exposure to biotin-horseradish
peroxidase-chemiluminescence revealed the presence of bioti-
nylated (thus located on the surface) GRP78. Lack of vimentin
in the samples (not shown) indicated that only urothelial cells
and no lamina propria fibroblasts were collected. In addition,
our previous experiment showed that only the superficial layer
of the urothelium is biotinylated[11]. Figure 2B shows
representative results of a biotinylation experiment. A faint
band showing biotinylation is present at 78 kDa (corresponding
to GRP78, indicated by arrow) in saline-treated bladders
whereas SP treatment resulted in a band of greater intensity
(asterisk).
Intraluminal antibodies to CD74 or GRP78 alone had no
effect
All of the different experimental groups and intraluminal
treatments are listed in Table 1. We examined possible non-
specific effects of intraluminal antibody (ab) treatment in rats
treated with saline alone. Table 2 shows levels of urothelial MIF,
released (intraluminal) MIF and bladder score in 3 controls
groups: 1) Saline (subcutaneous; s.c.)+Sal (intraluminally); 2) Saline
(s.c.)+CD74 ab (intraluminally) and 3) Saline (s.c.)+anti-GRP78 ab
(intraluminally). Intraluminal antibodies to CD74 or GRP78 did
not result in significant changes in any of these three measures
when compared to saline treatment, as determined by Analysis of
Variance (ANOVA; Table 2). Therefore, data from controls
groups were pooled for further analysis.
Anti-CD74/GRP78 Block SP
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substance P-induced urothelial MIF release
Substance P decreased MIF levels in urothelial cells compared
to controls (Fig 3A) indicating MIF release from these cells into the
intraluminal fluid. Intraluminal CD74 ab and/or GRP78 ab
prevented SP’s effects, whereas intraluminal non-specific immu-
noglobulin G (IgG) was not effective. Intraluminal CD74 ab or
CD74 ab+GRP78 ab caused an increase in urothelial MIF, when
compared to controls.
Concomitantly with decreased urothelial MIF levels, SP
treatment significantly increased intraluminal (released) MIF
compared to controls (Fig 3B). Intraluminal CD74 ab and CD74
ab+GRP78 ab prevented this increase while intraluminal GRP78
ab alone reduced (but did not prevent) intraluminal MIF release.
Intraluminal antibodies to CD74 and GRP78 reduced
substance P-induced histological changes
Bladder sections from all groups were stained with H&E and
evaluated by an observer (blinded as to the treatment) for
histological changes. SP treatment produced sub-mucosal edema
and vascular congestion resulting in a higher bladder score
compared to control groups (Fig 4A;C). Intraluminal CD74 ab
Figure 1. Substance P-induced MIF and GRP78 in umbrella cells. Single panels illustrating MIF (FITC labeling), GRP78 (TRITC labeling) and
overlay of both (using Leica Imaging Software). Exposure times were constant for each particular fluorochrome and images were uniformly adjusted
for brightness and contrast (Adobe Photoshop Elements v.2; Adobe Systems, San Jose, CA). Control sections where primary antibodies had been
omitted showed no MIF (A) or GRP78 immunofluorescence (B). Consequently, overlay panel also shows no immunofluorescence (C). Arrows mark
luminal edge of urothelium and slight autofluorescence can be seen. Representative sections showing urothelial immunostaining in saline-treated
(D–F) and substance P-treated (G–L) bladders. Saline treated bladders showed MIF (D) immunostaining in the urothelium, whereas the urothelium
appeared devoid of GRP78 immunostaining (E). Note MIF staining in basal and intermediate cells and light (or non-existent) immunostaining in
umbrella cells (D). Overlay panel shows only MIF immunostaining (F). Arrowheads show location of the lamina propria, showing MIF immunostaining
(D). In substance P-treated bladders, on the other hand, both MIF (G,J) and GRP78 (H,K) immunostaining was readily seen in the urothelium,
particularly in umbrella cells (arrows). Overlay shows simultaneous MIF and GRP78 immunostaining as an orange color (indicated by asterisks; I,L). MIF
only (panel I; green arrow) and GRP78 only (panel L; red arrow) umbrella cells can also be seen in the overlay panels. When compared to saline-
treated bladders (D) MIF immunostaining in substance P-treated bladders is also increased in the fibroblast layer of the lamina propria (arrowheads,
G,J). Calibration bar=50 mm.
doi:10.1371/journal.pone.0005835.g001
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significantly different from controls) and a combination of
antibodies (CD74+GRP78; Fig. 4A;F) significantly decreased
bladder scores compared to SP. Intraluminal IgG had no effect
on SP-induced changes (Fig 4A;G). Representative bladder
sections from each of the treatment groups are presented in
Fig 4B–G.
Intraluminal antibodies to CD74 or GRP78 reduced
substance P-induced expression of inflammatory markers
in urothelium
Substance P treatment significantly upregulated (.10-fold
change; p,.001) many inflammatory markers in urothelial cells
as detected by RT-PCR array, including MIF, INF-c, TNF-a, IL-
1b and CXCL-2 (Table 3A). Table 3A presents changes in SP-
induced expression of all markers studied as a function of
intraluminal treatment. All expression is normalized to expression
in the control group (Saline (s.c.)/Saline (intraluminally). SP, in
animals that received only intraluminal saline as a treatment,
significantly upregulated most of the inflammatory markers
studied (Table 3A). However, intraluminal CD74 ab prevented
or reduced expression of inflammatory markers. Similarly,
treatment with intraluminal GRP78 ab was effective in preventing
or reducing SP-induced expression. However, GRP78 ab also
produced increased expression (compared to SP/Saline treatment)
in certain markers (denoted with asterisk). Therefore, the effects of
CD74 ab and GRP78 ab were not identical.
The information in table 3 is also presented in the form of a
volcano plot[20]. Figure 5A shows upregulated markers in SP
treated (intraluminal saline) compared to saline treatment.
Intraluminal CD74 ab or GRP78 ab (Fig 5B;C) markedly reduced
the number of inflammatory markers upregulated, with some
showing significant downregulation. Finally, table 3B lists markers
that were not upregulated (,10 fold and/or p,0.001) by SP
treatment.
Discussion
In the present study we show that SP treatment induced
expression of GRP78 in umbrella cells, which also showed MIF
immunostaining. Moreover, GRP78-MIF and GRP78-A1-I3
complexes were detected from bladder homogenates. Finally, in
vivo biotinylation experiments showed that SP induced GRP78
expression in the cell surface of urothelial cells. Cell-surface
expression of GRP78 receptors in epithelial cells from pelvic
viscera has been reported[21–23] and mediates signal transduc-
tion[21]. Thus, our present findings, novel for the bladder during
inflammation, confirm other reports for pelvic viscera.
Our results also show MIF is released specifically from
urothelial cells during inflammation. Earlier work had shown
constitutive MIF expression in urothelial cells[10], decreased
bladder homogenate MIF and increased intraluminal (released)
MIF[3,5] and upregulated MIF mRNA in urothelial cells[11].
Examining isolated urothelial cells (this study), demonstrated that
treatment with SP decreases MIF levels in these cells, while
increasing released MIF. Therefore, while not ruling out a
contribution from the rest of bladder to MIF release, our evidence
clearly shows that the urothelium contributes significantly to MIF
release during inflammation. Released MIF and MIF-A1-I3
complexes are available to bind to urothelial (cell-surface) CD74
and GRP78 and possibly activate a pro-inflammatory cascade in
the bladder. Therefore, the function of these receptors during
bladder inflammation was examined using intraluminal antibodies
to both receptors.
In support of our hypothesis, intraluminal antibodies to CD74
and/or GRP78 prevented SP induced changes, namely: 1) MIF
release from urothelial cells 2) reduced or prevented histological
bladder changes and 3) decreased expression of inflammatory
Figure 2. GRP78-MIF complexes in the bladder. A) Representative
results of GRP78 ‘‘pull-down’’ experiments where GRP78 complexes
were isolated from bladder homogenates by immunoprecipitation and
then MIF (left side of figure) or A1-I3 (right side of figure) western
blotting was carried out to identify complexes. Recombinant MIF was
loaded (1
st lane) as positive control. Note that GRP78-MIF complexes
(marked by ## at 12 kDa, lane marked Sal=Saline) increased after
substance P treatment (lane labeled SP). A1-I3 western blotting (right
side) showed several fragments associated with GRP78, as expected,
since GRP78 is a receptor for A1-I3. Also note that while 12 kDa MIF was
not detected, several high-molecular weight fragments contained both
MIF and A1-I3 (130 and 80 kDa), as reported previously[9]. B) GRP78-MIF
complexes at the urothelial cell-surface. Urothelial cell-surface proteins
were biotinylated, isolated and then GRP78 biotinylated complexes
were ‘‘pulled down’’ using GRP78 antibodies. The resultant protein
complexes were then electrophoresed and biotin activity was detected
using biotin-horseradish peroxidase-chemiluminescence. A faint band
of biotinylated (cell-surface) proteins at approximately 78 kDa (corre-
sponding to GRP78 molecular weight) were ‘‘pulled down’’ by GRP78
immunoprecipitation in saline animals, while this band increased in
intensity in substance P-treated animals (asterisk). Therefore, these
results show that GRP78-MIF urothelial cell-surface complexes increase
after substance P-treatment.
doi:10.1371/journal.pone.0005835.g002
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non-specific IgG was not effective in preventing SP-induced
changes and also that antibodies to CD74 or GRP78 did not, by
themselves, alter bladder parameters measured in this study, we
conclude that the effects of antibodies to CD74 and GRP78 were
specific to MIF-receptor interactions. Interestingly, intraluminal
antibodies to CD74 (either alone or in combination with GRP78)
increased urothelial MIF content suggesting that activation of
CD74 regulates MIF release. We also recently observed in vitro
that reducing CD74 mRNA (using RNA interference) upregulated
MIF in prostate cancer cells [24]. While it is possible that CD74
may act as cargo molecule for MIF and thus modulate MIF release
from urothelial cells, this possibility remains to be tested. However,
we recently provided evidence that substance P induced urothelial
surface expression of CD74[11]. Therefore, it is possible that
activation of urothelial cell-surface CD74 (MIF’s receptor) but not
GRP78 (MIF-A1-I3 complex receptor) modulates MIF’s release
from the cell and MIF production inside the cell, with receptor
down-regulation (or blockade) increasing MIF expression. Regu-
lating MIF expression may thus play a role in inflammation
(present results) and carcinogenesis[24].
Intraluminal antibodies to MIF prevented or reduced SP-
induced inflammatory changes in the bladder[5]. Our present
results extend those findings since intraluminal antibodies to
CD74 (receptor for MIF) and/or antibodies to GRP78 (receptor
for MIF-A1-I3 complexes) were also effective in reducing of
preventing inflammatory effects of SP in the bladder. Taken
together, our results show that preventing MIF from binding to
specific urothelial receptors reduces or prevents cystitis.
Although the present study focused on CD74 (canonical MIF
receptor) and described a novel MIF-complex receptor
(GRP78), it is likely that other urothelial receptors may bind
MIF and thus participate in MIF-mediated signaling in the
bladder. CXCR2 and CXCR4 have recently been described as
non-canonical MIF receptors[14,25], and CXCR4 was recently
shown to be located in the normal urothelium, to bind to MIF
and to be upregulated during bladder inflammation[15].
CXCR2 is also expressed by urothelial cells[26] and may also
be involved in this process. Therefore, future investigations into
the specific role of these urothelial receptors in MIF-mediated
signal transduction in the bladder should increase our
understanding of MIF-mediated signaling during bladder
inflammation.
Conclusions
Constitutively expressed urothelial MIF is released by SP and
participates in bladder inflammation (either maintaining or
enhancing inflammation) by interacting with luminal cell-surface
receptors CD74 and GRP78.
Materials and Methods
Ethics Statement
All experiments were conducted after obtaining Institutional
Animal Care and Use committee approval (protocol #2643) and
conformed to the National Institutes of Health Guide for animal
experimentation.
Substance P-induced bladder inflammation
In anesthetized rats (male Sprague-Dawley; 300–350 gm;
Harlan, IN; sodium pentobarbital; 60 mg/kg; i.p.), the bladder
was exposed by abdominal incision and ureters were cut to isolate
Table 1. Experimental design for different intraluminal treatments and their effects on substance P-induced bladder inflammation.
Experimental Groups Treatment (s.c.) Treatment (intraluminal)
N=5 Substance P (40 ug/kg) Saline (0.3 ml)
N=5 Substance P (40 ug/kg) CD74 ab (15 mg/kg; 0.3 ml)
1
N=5 Substance P (40 ug/kg) GRP78 ab(15 mg/kg; 0.3 ml)
2
N=5 Substance P (40 ug/kg) CD74 ab+GRP78 ab (5 mg/kg; 0.3 ml)
N=5 Substance P (40 ug/kg) IgG (15 mg/kg; 0.3 ml)
3
Control Groups
N=5 Saline Saline (0.3 ml)
N=5 Saline CD74 ab (15 mg/kg; 0.3 ml)
1
N=5 Saline GRP78 ab (15 mg/kg; 0.3 ml)
2
1Goat polyclonal; Santa Cruz; sc-5438.
2Goat polyclonal; Santa Cruz; sc-1050.
3Goat non-specific IgG; Santa Cruz; sc-2028.
All antibodies were dialyzed to remove sodium azide. Final protein concentrations were determined from all samples (BCA, Thermo Scientific).
doi:10.1371/journal.pone.0005835.t001
Table 2. Mean and S.E.M for each parameter in control groups (N=5/group).
Sal(Sal) Sal(CD74) Sal(GRP) ANOVA
Urothelial MIF (ng MIF/mg prot) 39.98 (61.55) 44.98(68.0) 41.34(64.04) F=0.789 n.s.
Released(Intraluminal) MIF (ng MIF/ml) 4.04(60.65) 4.00(60.87) 3.47(60.99) F=0.865 n.s.
Bladder Score 1(60.32) 0.2(60.2) 1(60.32) F=0.110 n.s.
Abbreviations: Sal=Saline; CD74=CD74 antibody; GRP=GRP78 antibody.
doi:10.1371/journal.pone.0005835.t002
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intraluminal fluid. Urine was removed from the bladder using a
syringe (30 ga needle) and replaced with 0.3 ml of saline. Then
rats received either saline (0.1 ml/100 g body weight; s.c.; N=5)
or SP (Sigma; dissolved in saline; 40 mg/kg; 0.1 ml/100 g body
weight; s.c.; N=5)[3–5,7,9,16]. After 1 hour the intraluminal fluid
was collected and the bladder was excised and bisected
(longitudinally). Bladder halves were either placed in 4%
paraformaldehyde or processed for protein and/or mRNA.
MIF and GRP78 dual immunofluorescence
Frozen, coronal bladder sections (12 mm) from rats treated with
saline or SP were exposed simultaneously to MIF (1:200; rabbit
polyclonal; Torrey Pines Biolabs; Houston, TX) and GRP78
(1:200; goat polyclonal; sc-1050; Santa Cruz Biotechnology; Santa
Cruz, CA) antibodies and visualized using appropriate secondary
antibodies conjugated to fluorescein isothiocyanate (FITC) or
tetramethylrhodamine isothiocyanate (TRITC; Jackson Immuno-
chemical; West Grove, PA). Primary or either secondary
Figure 3. Effect of different intraluminal treatments on substance P (SP)-induced urothelial MIF release. Intraluminal treatment for each
group is in parenthesis. A) Urothelial MIF is decreased after SP treatment, suggesting MIF release from the urothelium. This effect is prevented by
intraluminal treatment with CD74 ab (CD74), GRP78 ab (GRP) or a combination of both. Intraluminal treatment with non-specific IgG did not prevent
the decrease in urothelial MIF produced by SP. B) SP treatment significantly increased MIF in intraluminal fluid. Intraluminal treatment with CD74 ab
prevented this increase, whereas treatment with GRP-78 ab (GRP) decreased the amount of MIF in the intraluminal fluid (compared to SP only), but it
was still increased (compared to saline). Treatment with both CD74 ab and GRP78 ab (CD74+GRP) also prevented SP-induced MIF release.
Intraluminal non-specific IgG had no effect. *=comparison to saline p,0.05; ***=p,0.001; (#)=comparison to SP(Sal) p,0.05;(###)=p,0.001;
n.s.=not significant.
doi:10.1371/journal.pone.0005835.g003
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using a Leica DMI4000B (Leica Microsystems Inc, Wetzlar,
Germany) microscope.
GRP78-MIF or GRP78-A1-I3 complex detection using co-
immunoprecipitation followed by Western blotting
GRP78 protein complexes were isolated from rat bladder
homogenates (250 mg protein) by first immunoprecipitating using
GRP78 polyclonal antibody (5 mg) and protein G agarose.
Resultant protein complexes were separated by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred to polyvinylidene difluoride (PVDF) membranes.
GRP78-MIF or GRP78-A1-I3 complexes were detected using
using Western blotting with either MIF biotinylated goat
polyclonal antibody (R&D Systems; Minneapolis, MN, BAF289)
or A1-I3 rabbit polyclonal antibody (a gift from Professor Harry
Figure 4. Effect of different intraluminal treatments on substance P (SP)-induced histological changes. A) Bladder inflammation scores
across all treatment groups (intraluminal treatment for each group is in parenthesis). Substance P produced bladder edema and inflammation when
compared to the control group. Groups treated with CD74 ab (CD74) and/or GRP78 ab (GRP) had bladder scores that were not significantly different
from control. B–G. Representative H&E stained bladder sections from each group. *=comparison to saline p,0.05; ***=p,0.001; (#)=comparison
to SP(Sal) p,0.05;(###)=p,0.001; n.s.=not significant.
doi:10.1371/journal.pone.0005835.g004
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PLoS ONE | www.plosone.org 7 June 2009 | Volume 4 | Issue 6 | e5835Table 3. Changes in substance P-induced expression of inflammatory markers in urothelial cells as a result intraluminal treatment.
Intravesical Treatment Intravesical Treatment
SALINE CD74 GRP78 SALINE CD74 GRP78
A. UPREGULATED
Chemokines Cytokines
Ccl17 7140 29 14 Ifng 19032 519 33199
*
Il13 6671 37 2 Il11 18828 749 1
Cxcl5 4211 60 24 Il18 15857 324 2422
Ccl19 3433 6 23 Il1f6_predicted 15215 34 102360
*
Cxcl10 3377 8 18806
* Il5 14053 21 1768
Cxcl11 3121 474 6 Il17b 9607 64 14
Ccl11 2825 387 21T n f 9240 23 169
Cxcl2 2697 2 410 Itgam 6360 8 22
Ccl7 1630 13 4 Tnfsf5 4280 2 4683
*
Ccl2 1447 10 502 Il3 4224 501 22
Ccl9 1311 22 27 Il1a 2503 56 82
Ccl24 1225 5 1 Il1b 2372 109 27
Ccl20 851 95 22 Il16_mapped 2179 5 27
Ccl21b 813 19 313 Il4 2162 57 1379
Ccl3 619 216 214 Spp1 1684 1 25
Cxcl1 580 1 1 Lta 1456 35 26
Cxcl12 122 26 263 Il10 1133 32 2
Pf4 37 22 467
* Itgb2 647 28 226
Ccl5 24 23 221 Il1f5_predicted 194 221
Chemokine Receptors Ltb 179 12 5
Cx3cr1 20715 386 1 Mif 149 34 2102
Il8rb 10866 41 22 Scye1 70 2281 2116
Ccr8_predicted 7424 23 21 Cytokine Receptors
Il8ra 5687 21 24 Il1r2 13245 109 22
Xcr1_predicted 5192 68 22 Il5ra 11039 327 2549
Ccr4 3881 110 808 Il2rb 6345 38 2
Ccr3 2207 210 26 Tnfrsf1a 3585 5 24
Ccr7 2056 211 15514
* Il13ra1 2894 74 23
Ccr2 1835 16 3 Il2rg 1217 167 52
Ccr6 1714 28 23457
* Tnfrsf1b 620 11 231
Ccr5 857 2 215 Il10ra 142 6 55
Cxcr3 707 14 9448
* Il1r1 69 295
Ccr9 389 21 4888
* Il6r 20 21 22
Gpr2_predicted 261 4 3 Il6st 19 22 2579
Others
Crp 14553 659 160
C3 3366 55 6
B. UNCHANGED
Chemokines Chemokine Receptors
Ccl12_predicted 162 1 228 Ccr1 763 62 27
C5 60 2 1 Cytokines
Ccl6 29 219 222 Tgfb1 6 221 7
Ccl4 27 1 12 Others
Ccl22 27 2 3 Casp1 85 215 4
Ccl25 20 27 2103 Tollip_predicted 15 279 21178
Cx3cl1 9 23 21 Bcl6_predicted 5 280 255
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chemiluminescent substrate (Pierce, Rockford, IL). Bands were
visualized and quantified using Kodak Image Station (Kodak,
Rochester, NY) and included software.
In vivo biotinylation of luminal cell-surface proteins
We used in vivo biotinylation of luminal cell-surface proteins as
we described recently[11]. Briefly, rats were divided into saline
(N=5) or SP (N=5) groups as described above. Bladders were
emptied of urine, rinsed twice with PBS and filled with
biotinylation reagent (1 mg/ml N-hydroxysulfosuccinimide biotin
ester, Pierce Biochemicals, Rockford, IL; 0.3 ml). After 1 hour the
bladders were excised, carefully stretched and urothelial cells
collected by scraping (epithelial aggregate separation and isolation;
EASI)[27]. Remaining bladder pieces were fixed in formalin and
frozen sections stained with hematoxylin and eosin (H&E) to
document that only epithelium was removed. Also, western-
blotting using anti-vimentin (a fibroblast marker) was used to verity
that only urothelial cells were isolated[11]. Isolated urothelial cells
were collected by centrifugation at 10,000 g (5 min), washed (3x)
in PBS pH 8.0 to inactivate residual biotinylation reagent. Cells
were lysed with SDS and homogenates were immunoprecipitated
with anti-GRP78 antibodies (described above). After electropho-
resis and transfer to PDVF membranes, biotinylated surface
proteins were visualized using only chemiluminescent substrate in
the Kodak Image Station.
Effects of intraluminal antibodies to GRP78 and/or CD74
on SP-induced urothelial MIF release, bladder histological
changes and urothelial expression of inflammatory
markers
Table 1 lists intraluminal antibody treatments in experimental
and separate control groups (testing for possible effects of
intraluminal treatment alone in the absence of SP). Saline (s.c.)
or SP (s.c.) administration to the groups was as described above.
One hr after SP treatment, intraluminal fluid was collected and
bladders excised. Urothelial cells were collected from half of the
bladder using the EASI procedure (see above) while the other half
of the bladder (intact) was placed in paraformaldehyde. Intralu-
minal fluid and urothelial cell homogenates were processed for
MIF protein using enzyme-linked immunosorbent assay
(ELISA)[15].
To assess changes in urothelial expression of inflammatory
markers, total RNA (1 mg) from scraped urothelial cells from
animals in each of the following groups: SP (s.c.)/Saline
(intraluminal), SP (s.c.)/Anti-CD74 (intraluminal), SP (s.c.)/Anti-
GRP78 (intraluminal) and Saline (s.c.)/Saline (intraluminal) were
separately pooled and reverse transcribed (RT
2 First strand kit, C-
03, SABiosciences, Fredrick, MD). The resulting cDNA was used
in a PCR array (repeated 3 times; Inflammatory Cytokines and
Receptors, PARN-011, SA Bioscience) and analyzed using
GEarray Expression Analysis Suite (http://geasuite.superarray.
com/; SABiosciences). Gene expression was normalized to
ribosomal protein RPL13A. 10-fold gene expression changes
(significant at p,0.001) when compared to Saline (s.c.)/Saline
(intraluminal) were considered significant.
Bladder histological changes were assessed in frozen bladder
sections (12 mm; groups in Table 1) counterstained with H&E and
examined by an observer blinded to experimental treatment and
received a score of: 0=no edema, normal appearance; 1=slight
submucosal edema and vascular congestion, but not present
uniformly; 2=moderate submucosal edema and vascular conges-
tion; 3=severe submucosal edema, vascular congestion, partial
loosening of intercellular urothelial junction.
Data analyses
Data presented are Mean6S.E.M. ANOVA followed by Tukey
Honest Significant Difference tests were performed using statistical
software (R; http://www.r-project.org/). Gene expression changes
were analyzed using GEarray Expression Analysis Suite (http://
geasuite.superarray.com/; SABiosciences). A 10-fold gene expres-
sion change with a t-test showing p,0.001 was considered
significant. The effect of intraluminal treatment on SP-induced
inflammatory gene expression changes were plotted using a
volcano plot[20]. A volcano plot identifies significance and
magnitude of change in expression of a set of genes between two
conditions. It is a scatter plot of the negative log10 transformed p-
values from a t test on the y-axis against the log2 fold change
between the two conditions on the x-axis. The x-axis indicates
biological impact of the change; the y-axis indicates the statistical
evidence, or reliability of the change. Genes with statistically
significant differential expression according to the gene specific t-
test will lie above a horizontal threshold line (set at 10-fold). Genes
with large fold-change values will lie outside a pair of vertical
threshold lines (set at p,0.001). The significant genes identified by
the t-test will tend to be located in the upper left or upper right
parts of the volcano plot.
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Intravesical Treatment Intravesical Treatment
SALINE CD74 GRP78 SALINE CD74 GRP78
Cxcl9 21 3 3 Blr1 237 240 25
Expression is calculated as fold-change over control treatment, Saline (s.c.)/Saline (intraluminal). Significant changes (highlighted in italicized bold) were defined as .10-
fold expression and with p,0.001. Asterisks after individual markers in GRP78 ab treatment group denote increased SP-induced expression over Saline treatment that
differed from CD74 ab.
doi:10.1371/journal.pone.0005835.t003
Table 3. Cont.
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Figure 5. Volcano Plots of inflammatory gene array changes. For each plot, fold change in expression for each of the inflammatory cytokines
studied (Table 2) is plotted on the abscissa while t-test significance is plotted on the y-axis. In all three plots, comparison of gene expression is made
to control group (Sal (s.c.)/Sal(intraluminal). A significant change was arbitrarily defined as a 10-fold difference (vertical lines) AND a p,0.001
(horizontal line). Using these criteria then, significant changes have been plotted using red markers, while non-significant changes are plotted using
blue markers. A) Substance P treatment with saline as an intraluminal treatment (SP=Substance P(s.c.)/Saline (intraluminal) upregulated many
inflammatory genes (red points in upper right quadrant). B) Intraluminal CD74 ab treatment, in SP treated rats (SP+CD74) reduced the number of
inflammatory genes upregulated by SP. C) Similarly, intraluminal GRP78 ab treatment also reduced the number of genes upregulated by SP with
some showing significant downregulation (red points in upper left quadrant).
doi:10.1371/journal.pone.0005835.g005
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